Tata Chemicals Board Approves Financial Results and Recommends Dividend for FY 2025-26

Tata Chemicals Limited has announced its financial results for the quarter and year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹11 per share, representing a 110% payout for the 2025-26 financial year. Despite facing challenging market conditions, the company continues to focus on strategic growth and operational efficiency as it navigates a complex global landscape.

Financial Performance Summary

For the fiscal year ended March 31, 2026, Tata Chemicals reported consolidated revenue from operations of ₹14,584 crore. The company faced a consolidated net loss after tax of ₹1,715 crore for the year, largely impacted by significant exceptional items, including an impairment charge of ₹1,837 crore related to goodwill in its US operations.

Dividend Recommendation

Demonstrating its commitment to shareholder value, the Board has recommended a final dividend of ₹11.00 per share (110%) for the 2025-26 financial year. This dividend is subject to approval by shareholders at the company’s upcoming 87th Annual General Meeting (AGM) and will be payable within five days of that meeting.

Segment Insights

The company operates across two primary segments: Basic Chemistry Products and Specialty Products. The Basic Chemistry segment remains a core driver of revenue, contributing ₹11,521 crore to the annual consolidated revenue, while the Specialty Products segment saw growth, contributing ₹3,076 crore to the annual turnover.

Strategic Developments

During the fiscal year, the company navigated several operational adjustments, including the ongoing closure of its Lostock plant in the United Kingdom. Additionally, the group recognized a non-recurring impact of ₹54 crore related to the implementation of new Labour Codes in India. Management continues to monitor global market conditions and geopolitical developments to ensure long-term sustainability and operational resilience.

Source: BSE

Previous Article

Aurobindo Pharma CEO of Apitoria Pharma Resigns

Next Article

Aarti Industries Fiscal Year 2026 Financial Results and Dividend Announcement